Clinical trials: Idiopathic CD4-Positive, open to volunteers
ICL, Vault
Predictive Performance of a Generative Model for Corneal Tomography After ICL Implantation
To evaluate the efficacy of a corneal tomography Imaging model in predicting postoperative vault based on preoperative corneal topography in Implantable Collamer Lens (ICL) surgery.
- Conditions
- ICL, Vault, Deep Learning, AI (Artificial Intelligence)
- Trial name
- NCT07146737
- Testing
- Corneal tomography generation model after ICL surgery
- Where
- China
- Volunteers
- 818 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Idiopathic CD4-Positive, T-Lymphocytopenia
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Idiopathic CD4 lymphocytopenia (ICL) is a rare syndrome defined by consistently low CD4 T cell counts (<300/mm^3) without evidence of HIV infection or other known immunodeficiency.
- Trial name
- NCT02015013
- Testing
- Filgrastim, Plerixafor
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Idiopathic CD4+ Lymphocytopenia, Cryptococcal Meningitis
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Background: Idiopathic CD4+ lymphocytopenia (ICL) is a condition in which there is a decreased level of CD4+ lymphocytes (a type of white blood cell), which can lead to opportunistic infections or autoimmune disorders and…
- Conditions
- Idiopathic CD4+ Lymphocytopenia, Cryptococcal Meningitis, Warts
- Trial name
- NCT00867269
- Where
- United States
- Volunteers
- 950 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Idiopathic CD4 Lymphopenia
A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia
Background: Idiopathic CD4 lymphopenia (ICL) is a syndrome characterized by low levels of certain immune cells called CD4 T cells.
- Trial name
- NCT05600920
- Testing
- Recombinant human interleukin (IL) 7-hyFc
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Idiopathic CD4 Lymphopenia
Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)
Background: People with Idiopathic CD4 lymphopenia (ICL) have lower numbers of a type of white blood cell called CD4 cells. White blood cells fight against infections.
- Trial name
- NCT04097561
- Testing
- Belimumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)